Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: A phase 1/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy])

Circulation Research

Volumn 121, Issue 10, 2017, Pages 1192-1204

  Bartolucci, Jorge ^a,b   Verdugo, Fernando J ^a   González, Paz L ^a,c   Larrea, Ricardo E ^a,d   Abarzua, Ema ^b   Goset, Carlos ^b   Rojo, Pamela ^d   Palma, Ivan ^d   Lamich, Ruben ^b   Pedreros, Pablo A ^b   Valdivia, Gloria ^b   Lopez, Valentina M ^e   Nazzal, Carolina ^f   Alcayaga Miranda, Francisca ^a,c   Cuenca, Jimena ^a,c   Brobeck, Matthew J ^g   Patel, Amit N ^h   Figueroa, Fernando E ^a,c   Khoury, Maroun ^a,c,e  

^a UNIVERSIDAD DE LOS ANDES   (Chile)

^b CLÍNICA SANTA MARÍA   (Chile)

^c Clínica Santa Maria ^*  (Chile)

^d Section of Gastroenterology   (Chile)

^e Chilean Consortium for Regenerative Medicine   (Chile)

^f UNIVERSITY OF CHILE   (Chile)

^g UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiomyopathies; Clinical trial; Heart failure; Mesenchymal stromal cells; Umbilical cord

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CLONOGENESIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EVALUATION STUDY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART ARRHYTHMIA; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INCIDENTAL FINDING; INTRAVENOUS DRUG ADMINISTRATION; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MALE; MALIGNANT NEOPLASM; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; MORTALITY RATE; MULTICENTER STUDY; NEW YORK HEART ASSOCIATION CLASS; NORMAL HUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRODUCT SAFETY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TRANSTHORACIC ECHOCARDIOGRAPHY; UMBILICAL CORD DERIVED MESENCHYMAL STEM CELL; YOUNG ADULT; AGED; CELL MOTION; CLINICAL TRIAL; MESENCHYMAL STROMA CELL; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION; TREATMENT OUTCOME; UMBILICAL CORD;

AGED; CELL MOVEMENT; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; TREATMENT OUTCOME; UMBILICAL CORD;

EID: 85032618937     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.310712     Document Type: Article

References (49)

1. Williams AR, Hare JM. Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011;109:923-940. doi: 10.1161/CIRCRESAHA.111.243147.
2. Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res. 2013;113:810-834. doi: 10.1161/CIRCRESAHA.113.300219.
3. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012;126:551-568. doi: 10.1161/CIRCULATIONAHA.111.086074.
4. Kandala J, Upadhyay GA, Pokushalov E, Wu S, Drachman DE, Singh JP. Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol. 2013;112:217-225. doi: 10.1016/j.amjcard.2013.03.021.
5. Gho JM, Kummeling GJ, Koudstaal S, Jansen Of Lorkeers SJ, Doevendans PA, Asselbergs FW, Chamuleau SA. Cell therapy, a novel remedy for dilated cardiomyopathy? A systematic review. J Card Fail. 2013;19:494-502. doi: 10.1016/j.cardfail.2013.05.006.
6. Fisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116:1361-1377. doi: 10.1161/CIRCRESAHA.116.304386.
7. Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, Bieback K, Wang W, Klopsch C, Ong LL, Li W, Ma N, Steinhoff G. Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS One. 2011;6:e15652. doi: 10.1371/journal.pone.0015652.
8. Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008;102:1319-1330. doi: 10.1161/CIRCRESAHA.108.175943.
9. Nishiyama N, Miyoshi S, Hida N, Uyama T, Okamoto K, Ikegami Y, Miyado K, Segawa K, Terai M, Sakamoto M, Ogawa S, Umezawa A. The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro. Stem Cells. 2007;25:2017-2024. doi: 10.1634/stemcells.2006-0662.
10. Ramkisoensing AA, Pijnappels DA, Askar SF, Passier R, Swildens J, Goumans MJ, Schutte CI, de Vries AA, Scherjon S, Mummery CL, Schalij MJ, Atsma DE. Human embryonic and fetal mesenchymal stem cells differentiate toward three different cardiac lineages in contrast to their adult counterparts. PLoS One. 2011;6:e24164. doi: 10.1371/journal.pone.0024164.
11. Santos Nascimento D, Mosqueira D, Sousa LM, Teixeira M, Filipe M, Resende TP, Araújo AF, Valente M, Almeida J, Martins JP, Santos JM, Bárcia RN, Cruz P, Cruz H, Pinto-do-Ó P. Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms. Stem Cell Res Ther. 2014;5:5. doi: 10.1186/scrt394.
12. González PL, Carvajal C, Cuenca J, Alcayaga-Miranda F, Figueroa FE, Bartolucci J, Salazar-Aravena L, Khoury M. Chorion mesenchymal stem cells show superior differentiation, immunosuppressive, and angiogenic potentials in comparison with haploidentical maternal placental cells. Stem Cells Transl Med. 2015;4:1109-1121. doi: 10.5966/sctm.2015-0022.
13. Gong X, Wang P, Wu Q, Wang S, Yu L, Wang G. Human umbilical cord blood derived mesenchymal stem cells improve cardiac function in cTnT(R141W) transgenic mouse of dilated cardiomyopathy. Eur J Cell Biol. 2016;95:57-67. doi: 10.1016/j.ejcb.2015.11.003.
14. Liu CB, Huang H, Sun P, Ma SZ, Liu AH, Xue J, Fu JH, Liang YQ, Liu B, Wu DY, Lü SH, Zhang XZ. Human umbilical cord-derived mesenchymal stromal cells improve left ventricular function, perfusion, and remodeling in a porcine model of chronic myocardial ischemia. Stem Cells Transl Med. 2016;5:1004-1013. doi: 10.5966/sctm.2015-0298.
15. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-317. doi: 10.1080/14653240600855905.
16. Banovic M, Loncar Z, Behfar A, Vanderheyden M, Beleslin B, Zeiher A, Metra M, Terzic A, Bartunek J. Endpoints in stem cell trials in ischemic heart failure. Stem Cell Res Ther. 2015;6:159. doi: 10.1186/s13287-015-0143-9.
17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463. doi: 10.1016/j.echo.2005.10.005.
18. Mor-Avi V, Lang RM, Badano LP, et al. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr. 2011;24:277-313. doi: 10.1016/j.echo.2011.01.015.
19. Heiberg E, Sjögren J, Ugander M, Carlsson M, Engblom H, Arheden H. Design and validation of Segment-freely available software for cardiovascular image analysis. BMC Med Imaging. 2010;10:1. doi: 10.1186/1471-2342-10-1.
20. Garin O, Soriano N, Ribera A, Ferrer M, Pont A, Alonso J, Permanyer G; Grupo IC-QoL. [Validation of the Spanish version of the Minnesota Living with Heart Failure Questionnaire]. Rev Esp Cardiol. 2008;61:251-259. doi: 10.1016/S1885-5857(08)60112-7.
21. Comín-Colet J, Garin O, Lupón J, Manito N, Crespo-Leiro MG, Gómez-Bueno M, Ferrer M, Artigas R, Zapata A, Elosua R; VALIC-KC Study Group. Validation of the Spanish version of the Kansas city Cardiomyopathy Questionnaire. Rev Esp Cardiol. 2011;64:51-58. doi: 10.1016/j.recesp.2010.10.003.
22. Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7:e47559. doi: 10.1371/journal.pone.0047559.
23. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277-2286. doi: 10.1016/j.jacc.2009.06.055.
24. Butler J, Epstein SE, Greene SJ, Quyyumi AA, Sikora S, Kim RJ, Anderson AS, Wilcox JE, Tankovich NI, Lipinski MJ, Ko YA, Margulies KB, Cole RT, Skopicki HA, Gheorghiade M. Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy: safety and efficacy results of a phase II-a randomized trial. Circ Res. 2017;120:332-340. doi: 10.1161/CIRCRESAHA.116.309717.
25. Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308:2369-2379. doi: 10.1001/jama.2012.25321.
26. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61:2329-2338. doi: 10.1016/j.jacc.2013.02.071.
27. Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311:62-73. doi: 10.1001/jama.2013.282909.
28. Mathiasen AB, Qayyum AA, Jørgensen E, Helqvist S, Fischer-Nielsen A, Kofoed KF, Haack-Sørensen M, Ekblond A, Kastrup J. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015;36:1744-1753. doi: 10.1093/eurheartj/ehv136.
29. Zhao XF, Xu Y, Zhu ZY, Gao CY, Shi YN. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure. Genet Mol Res. 2015;14:3010-3017. doi: 10.4238/2015.April.10.11.
30. Hare JM, DiFede DL, Rieger AC, et al. Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM Trial. J Am Coll Cardiol. 2017;69:526-537. doi: 10.1016/j.jacc.2016.11.009.
31. Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, East C, Remmers AE, Goodrich J. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016;387:2412-2421. doi: 10.1016/S0140-6736(16)30137-4.
32. Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD. A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res. 2015;117:576-584. doi: 10.1161/CIRCRESAHA.115.306332.
33. Bartunek J, Terzic A, Davison BA, et al; CHART Program. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38:648-660. doi: 10.1093/eurheartj/ehw543.
34. Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, Li S, Papadimitriou L, Butler J. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016;1:510-518. doi: 10.1001/jamacardio.2016.1325.
35. Rostagno C, Galanti G, Comeglio M, Boddi V, Olivo G, Gastone Neri Serneri G. Comparison of different methods of functional evaluation in patients with chronic heart failure. Eur J Heart Fail. 2000;2:273-280. doi: 10.1016/S1388-9842(00)00091-X.
36. Sarullo FM, Fazio G, Brusca I, Fasullo S, Paterna S, Licata P, Novo G, Novo S, Di Pasquale P. Cardiopulmonary exercise testing in patients with chronic heart failure: prognostic comparison from peak VO2 and VE/VCO2 slope. Open Cardiovasc Med J. 2010;4:127-134. doi: 10.2174/1874192401004010127.
37. Forman DE, Guazzi M, Myers J, Chase P, Bensimhon D, Cahalin LP, Peberdy MA, Ashley E, West E, Daniels KM, Arena R. Ventilatory power: a novel index that enhances prognostic assessment of patients with heart failure. Circ Heart Fail. 2012;5:621-626. doi: 10.1161/CIRCHEARTFAILURE.112.968529.
38. Honold J, Fischer-Rasokat U, Seeger FH, Leistner D, Lotz S, Dimmeler S, Zeiher AM, Assmus B. Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor cells on cardiopulmonary exercise capacity in patients with chronic postinfarction heart failure. Clin Res Cardiol. 2013;102:619-625. doi: 10.1007/s00392-013-0574-1.
39. Huang J, Zhang Z, Guo J, Ni A, Deb A, Zhang L, Mirotsou M, Pratt RE, Dzau VJ. Genetic modification of mesenchymal stem cells overexpressing CCR1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ Res. 2010;106:1753-1762. doi: 10.1161/CIRCRESAHA.109.196030.
40. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002;105:93-98. doi: 10.1161/hc0102.101442.
41. Ahmet I, Sawa Y, Iwata K, Matsuda H. Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: a novel gene therapy for cardiomyopathy. J Thorac Cardiovasc Surg. 2002;124:957-963. doi: 10.1067/mtc.2002.126655..
42. Ahmet I, Sawa Y, Yamaguchi T, Matsuda H. Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg. 2003;75:1283-1287. doi: 10.1016/S0003-4975(02)04677-5.
43. Jayasankar V, Woo YJ, Pirolli TJ, Bish LT, Berry MF, Burdick J, Gardner TJ, Sweeney HL. Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure. J Card Surg. 2005;20:93-101. doi: 10.1111/j.0886-0440.2005.200373.x.
44. Yang ZJ, Chen B, Sheng Z, Zhang DG, Jia EZ, Wang W, Ma DC, Zhu TB, Wang LS, Li CJ, Wang H, Cao KJ, Ma WZ. Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium- and high-dose groups. Mol Biol Rep. 2010;37:2075-2081. doi: 10.1007/s11033-009-9665-5.
45. Hu ZP, Bao Y, Chen DN, Cheng Y, Song B, Liu M, Li D, Wang BN. Effects of recombinant adenovirus hepatocyte growth factor gene on myocardial remodeling in spontaneously hypertensive rats. J Cardiovasc Pharmacol Ther. 2013;18:476-480. doi: 10.1177/1074248413490832.
46. Kim SW, Jin HL, Kang SM, Kim S, Yoo KJ, Jang Y, Kim HO, Yoon YS. Therapeutic effects of late outgrowth endothelial progenitor cells or mesenchymal stem cells derived from human umbilical cord blood on infarct repair. Int J Cardiol. 2016;203:498-507. doi: 10.1016/j.ijcard.2015.10.110.
47. Chen J, Liu Z, Hong MM, Zhang H, Chen C, Xiao M, Wang J, Yao F, Ba M, Liu J, Guo ZK, Zhong J. Proangiogenic compositions of microvesicles derived from human umbilical cord mesenchymal stem cells. PLoS One. 2014;9:e115316. doi: 10.1371/journal.pone.0115316.
48. Premer C, Blum A, Bellio MA, Schulman IH, Hurwitz BE, Parker M, Dermarkarian CR, DiFede DL, Balkan W, Khan A, Hare JM. Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells. EBioMedicine. 2015;2:467-475. doi: 10.1016/j.ebiom.2015.03.020.
49. Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: the Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res. 2014;114:1302-1310. doi: 10.1161/CIRCRESAHA.114.303180.